Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 146

1.

miR-15 and miR-16 induce apoptosis by targeting BCL2.

Cimmino A, Calin GA, Fabbri M, Iorio MV, Ferracin M, Shimizu M, Wojcik SE, Aqeilan RI, Zupo S, Dono M, Rassenti L, Alder H, Volinia S, Liu CG, Kipps TJ, Negrini M, Croce CM.

Proc Natl Acad Sci U S A. 2005 Sep 27;102(39):13944-9. Epub 2005 Sep 15. Erratum in: Proc Natl Acad Sci U S A. 2006 Feb 14;103(7):2464.

2.

miR-125b and miR-155 contribute to BCL2 repression and proliferation in response to CD40 ligand (CD154) in human leukemic B-cells.

Willimott S, Wagner SD.

J Biol Chem. 2012 Jan 20;287(4):2608-17. doi: 10.1074/jbc.M111.285718. Epub 2011 Dec 2.

3.

Genomics of chronic lymphocytic leukemia microRNAs as new players with clinical significance.

Calin GA, Croce CM.

Semin Oncol. 2006 Apr;33(2):167-73. Review.

PMID:
16616063
4.

Therapeutic implications of activation of the host gene (Dleu2) promoter for miR-15a/16-1 in chronic lymphocytic leukemia.

Kasar S, Underbayev C, Yuan Y, Hanlon M, Aly S, Khan H, Chang V, Batish M, Gavrilova T, Badiane F, Degheidy H, Marti G, Raveche E.

Oncogene. 2014 Jun 19;33(25):3307-15. doi: 10.1038/onc.2013.291. Epub 2013 Sep 2.

5.

Aberrant microRNA expression in Chinese patients with chronic lymphocytic leukemia.

Zhu DX, Miao KR, Fang C, Fan L, Zhu W, Zhu HY, Zhuang Y, Hong M, Liu P, Xu W, Li JY.

Leuk Res. 2011 Jun;35(6):730-4. doi: 10.1016/j.leukres.2010.11.005. Epub 2010 Dec 3.

PMID:
21130495
6.

Role of miR-15/16 in CLL.

Pekarsky Y, Croce CM.

Cell Death Differ. 2015 Jan;22(1):6-11. doi: 10.1038/cdd.2014.87. Epub 2014 Jun 27. Review.

7.

Stromal cells modulate TCL1 expression, interacting AP-1 components and TCL1-targeting micro-RNAs in chronic lymphocytic leukemia.

Sivina M, Hartmann E, Vasyutina E, Boucas JM, Breuer A, Keating MJ, Wierda WG, Rosenwald A, Herling M, Burger JA.

Leukemia. 2012 Aug;26(8):1812-20. doi: 10.1038/leu.2012.63. Epub 2012 Mar 5.

PMID:
22460735
8.

Investigating the targets of MIR-15a and MIR-16-1 in patients with chronic lymphocytic leukemia (CLL).

Hanlon K, Rudin CE, Harries LW.

PLoS One. 2009 Sep 25;4(9):e7169. doi: 10.1371/journal.pone.0007169.

9.

The role of microRNA and other non-coding RNA in the pathogenesis of chronic lymphocytic leukemia.

Calin GA, Pekarsky Y, Croce CM.

Best Pract Res Clin Haematol. 2007 Sep;20(3):425-37. Review.

PMID:
17707831
10.

miR-181b as a therapeutic agent for chronic lymphocytic leukemia in the Eµ-TCL1 mouse model.

Bresin A, Callegari E, D'Abundo L, Cattani C, Bassi C, Zagatti B, Narducci MG, Caprini E, Pekarsky Y, Croce CM, Sabbioni S, Russo G, Negrini M.

Oncotarget. 2015 Aug 14;6(23):19807-18.

11.

miR-15a/16-1 influences BCL2 expression in keratocystic odontogenic tumors.

Diniz MG, Gomes CC, de Castro WH, Guimarães AL, De Paula AM, Amm H, Ren C, MacDougall M, Gomez RS.

Cell Oncol (Dordr). 2012 Aug;35(4):285-91. doi: 10.1007/s13402-012-0087-3. Epub 2012 Jun 9.

PMID:
22684875
12.

Tcl1 expression in chronic lymphocytic leukemia is regulated by miR-29 and miR-181.

Pekarsky Y, Santanam U, Cimmino A, Palamarchuk A, Efanov A, Maximov V, Volinia S, Alder H, Liu CG, Rassenti L, Calin GA, Hagan JP, Kipps T, Croce CM.

Cancer Res. 2006 Dec 15;66(24):11590-3.

13.

Loss of MIR15A and MIR16-1 at 13q14 is associated with increased TP53 mRNA, de-repression of BCL2 and adverse outcome in chronic lymphocytic leukaemia.

Lin K, Farahani M, Yang Y, Johnson GG, Oates M, Atherton M, Douglas A, Kalakonda N, Pettitt AR.

Br J Haematol. 2014 Nov;167(3):346-55. doi: 10.1111/bjh.13043. Epub 2014 Jul 18.

PMID:
25040181
14.

miR deregulation in CLL.

Balatti V, Pekarky Y, Rizzotto L, Croce CM.

Adv Exp Med Biol. 2013;792:309-25. doi: 10.1007/978-1-4614-8051-8_14. Review.

15.

DLEU2, frequently deleted in malignancy, functions as a critical host gene of the cell cycle inhibitory microRNAs miR-15a and miR-16-1.

Lerner M, Harada M, Lovén J, Castro J, Davis Z, Oscier D, Henriksson M, Sangfelt O, Grandér D, Corcoran MM.

Exp Cell Res. 2009 Oct 15;315(17):2941-52. doi: 10.1016/j.yexcr.2009.07.001. Epub 2009 Jul 8.

PMID:
19591824
16.

MicroRNA-223 expression is uniformly down-regulated in B cell lymphoproliferative disorders and is associated with poor survival in patients with chronic lymphocytic leukemia.

Zhou K, Yi S, Yu Z, Li Z, Wang Y, Zou D, Qi J, Zhao Y, Qiu L.

Leuk Lymphoma. 2012 Jun;53(6):1155-61. doi: 10.3109/10428194.2011.642303. Epub 2012 Jan 31.

PMID:
22145958
17.

The Akt/Mcl-1 pathway plays a prominent role in mediating antiapoptotic signals downstream of the B-cell receptor in chronic lymphocytic leukemia B cells.

Longo PG, Laurenti L, Gobessi S, Sica S, Leone G, Efremov DG.

Blood. 2008 Jan 15;111(2):846-55. Epub 2007 Oct 10.

18.

miR-143 is downregulated in cervical cancer and promotes apoptosis and inhibits tumor formation by targeting Bcl-2.

Liu L, Yu X, Guo X, Tian Z, Su M, Long Y, Huang C, Zhou F, Liu M, Wu X, Wang X.

Mol Med Rep. 2012 Mar;5(3):753-60. doi: 10.3892/mmr.2011.696. Epub 2011 Dec 6.

PMID:
22160209
19.

MicroRNA expression profiling identifies activated B cell status in chronic lymphocytic leukemia cells.

Li S, Moffett HF, Lu J, Werner L, Zhang H, Ritz J, Neuberg D, Wucherpfennig KW, Brown JR, Novina CD.

PLoS One. 2011 Mar 8;6(3):e16956. doi: 10.1371/journal.pone.0016956.

20.

Progress in BCL2 inhibition for patients with chronic lymphocytic leukemia.

Tam CS, Seymour JF, Roberts AW.

Semin Oncol. 2016 Apr;43(2):274-9. doi: 10.1053/j.seminoncol.2016.02.014. Epub 2016 Feb 6. Review.

PMID:
27040706

Supplemental Content

Support Center